This fact alone makes GERN very interesting:
Feb 28, 2017
Incyte’s 2016 revenues
“As we saw in the previous part of this series, Incyte (INCY) reported revenues of $1.1 billion for 2016. That converts to a rise of 47.0% in 2016 compared to $753.7 million in 2015. The rise comes with increasing demand for Jakafi, Incyte’s only product for the treatment of rare types of blood cancer that’s approved by the FDA (U.S. Food & Drug Administration) .....
“Jakafi revenues rose to $852.8 million in 2016 from $601.0 million in 2015. The rise was due to an increase in volume as well as price for the drug in the United States. Jakafi’s revenues are estimated to cross $1.0 billion in 2017 in the United States.”
http://marketrealist.com/2017/02/unders ... -for-2016/
Jakafi revenues
Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
-
Fishermangents
- Site Admin
- Posts: 529
- Joined: Thu Dec 03, 2015 3:39 pm
Re: Jakafi revenues
Compare market cap: INCY 25Bln, GERN 350Mln. Just the MF market. Geron goes after hematologic malignancies, such as MF, PV, ET, MDS, CML and AML, because imetelstat targets the malignant clone and therefor offers disease modifying activity. Jakafi isn't capable of that. And there is pre-clinical evidence that imetelstat makes cancer cells more sensitive for radiation, plus the potential upcoming AML combo with venetoclax. There is a lot of expansion in the air for Geron. Let's see what the Q2 review will bring us.